ANXA2 and malignant glioma: Annexin A2 (ANXA2) is a candidate biomarker for malignant gliomas that was additionally identified to be directly involved in angiogenesis-dependent invasion through the up-regulation of the vascular endothelial growth factor (VEGF) [79,80].